Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party

L. Bento, A. Boumendil, H. Finel, S. Le Gouill, S. Amorim, H. Monjanel, R. Bouabdallah, JO. Bay, E. Nicolas-Virelizier, G. McQuaker, G. Rossi, R. Johnson, A. Huynh, P. Ceballos, A. Rambaldi, E. Bachy, R. Malladi, K. Orchard, D. Pohlreich, H....

. 2017 ; 52 (8) : 1120-1125. [pub] 20170522

Language English Country England, Great Britain

Document type Comparative Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc18025002
E-resources Online Full text

NLK Free Medical Journals from 1997 to 1 year ago
Freely Accessible Science Journals from 1997 to 1 year ago
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 28530668
DOI 10.1038/bmt.2017.88
Knihovny.cz E-resources

Relapse remains the most common cause of treatment failure in patients receiving autologous stem cell transplantation (ASCT) for follicular lymphoma (FL). The aim of this study was to evaluate the effect of adding radioimmunotherapy or rituximab (R) to BEAM (carmustine, etoposide, ara-c, melphalan) high-dose therapy for ASCT in patients with relapsed FL. Using the European Society for Blood and Marrow Transplantation registry, we conducted a cohort comparison of BEAM (n=1973), Zevalin-BEAM (Z-BEAM) (n=207) and R-BEAM (n=179) and also a matched-cohort analysis of BEAM vs Z-BEAM including 282 and 154 patients, respectively. BEAM, Z-BEAM and R-BEAM groups were well balanced for age, time from diagnosis to ASCT and disease status at ASCT. The cumulative incidences of relapse (IR) at 2 years were 34, 34 and 32% for Z-BEAM, R-BEAM and BEAM, respectively. By multivariate analysis, there were no significant differences with Z-BEAM or R-BEAM compared with BEAM for IR, non-relapse mortality, event-free survival or overall survival. With the caveat that the limitations of registry analyses have to be taken into account, this study does not support adding radioimmunotherapy or R to BEAM in ASCT for relapsed FL. However, we cannot rule out the existence a particular subset of patients who could benefit from Z-BEAM conditioning that cannot be identified in our series, and this should be tested in a randomized trial.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025002
003      
CZ-PrNML
005      
20240516121150.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/bmt.2017.88 $2 doi
035    __
$a (PubMed)28530668
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bento, L $u Son Espases University Hospital, Palma de Mallorca, Spain.
245    10
$a Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party / $c L. Bento, A. Boumendil, H. Finel, S. Le Gouill, S. Amorim, H. Monjanel, R. Bouabdallah, JO. Bay, E. Nicolas-Virelizier, G. McQuaker, G. Rossi, R. Johnson, A. Huynh, P. Ceballos, A. Rambaldi, E. Bachy, R. Malladi, K. Orchard, D. Pohlreich, H. Tilly, F. Bonifazi, X. Poiré, F. Guilhot, A. Haenel, C. Crawley, B. Metzner, J. Gribben, NH. Russell, G. Damaj, K. Thomson, P. Dreger, S. Montoto,
520    9_
$a Relapse remains the most common cause of treatment failure in patients receiving autologous stem cell transplantation (ASCT) for follicular lymphoma (FL). The aim of this study was to evaluate the effect of adding radioimmunotherapy or rituximab (R) to BEAM (carmustine, etoposide, ara-c, melphalan) high-dose therapy for ASCT in patients with relapsed FL. Using the European Society for Blood and Marrow Transplantation registry, we conducted a cohort comparison of BEAM (n=1973), Zevalin-BEAM (Z-BEAM) (n=207) and R-BEAM (n=179) and also a matched-cohort analysis of BEAM vs Z-BEAM including 282 and 154 patients, respectively. BEAM, Z-BEAM and R-BEAM groups were well balanced for age, time from diagnosis to ASCT and disease status at ASCT. The cumulative incidences of relapse (IR) at 2 years were 34, 34 and 32% for Z-BEAM, R-BEAM and BEAM, respectively. By multivariate analysis, there were no significant differences with Z-BEAM or R-BEAM compared with BEAM for IR, non-relapse mortality, event-free survival or overall survival. With the caveat that the limitations of registry analyses have to be taken into account, this study does not support adding radioimmunotherapy or R to BEAM in ASCT for relapsed FL. However, we cannot rule out the existence a particular subset of patients who could benefit from Z-BEAM conditioning that cannot be identified in our series, and this should be tested in a randomized trial.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a karmustin $x terapeutické užití $7 D002330
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kombinovaná terapie $x metody $7 D003131
650    _2
$a cytarabin $x terapeutické užití $7 D003561
650    _2
$a etoposid $x terapeutické užití $7 D005047
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a transplantace hematopoetických kmenových buněk $x metody $x mortalita $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a folikulární lymfom $x mortalita $x terapie $7 D008224
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melfalan $x terapeutické užití $7 D008558
650    _2
$a lidé středního věku $7 D008875
650    _2
$a radioimunoterapie $x metody $7 D016499
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rituximab $x terapeutické užití $7 D000069283
650    _2
$a analýza přežití $7 D016019
650    _2
$a autologní transplantace $7 D014182
650    _2
$a mladý dospělý $7 D055815
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Boumendil, A $u EBMT LWP Office, Paris, France.
700    1_
$a Finel, H $u EBMT LWP Office, Paris, France.
700    1_
$a Le Gouill, S $u CHU, Nantes, France.
700    1_
$a Amorim, S $u Centre Hospitalier Saint-Louis, Paris, France.
700    1_
$a Monjanel, H $u Hôpital Bretonneau, Tours, France.
700    1_
$a Bouabdallah, R $u Institut Paoli Calmettes, Marseille, France.
700    1_
$a Bay, J O $u CHU, Clermont-Ferrand, France.
700    1_
$a Nicolas-Virelizier, E $u Centre Leon Berard, Lyon, France.
700    1_
$a McQuaker, G $u Gartnaval General Hospital, Glasgow, UK.
700    1_
$a Rossi, G $u Spedali Civili, Brescia, Italy.
700    1_
$a Johnson, R $u St James Institute of Oncology, Leeds, UK.
700    1_
$a Huynh, A $u Hôpital Purpan, Toulouse, France.
700    1_
$a Ceballos, P $u CHU Lapeyronie, Montpellier, France.
700    1_
$a Rambaldi, Alessandro $u Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. $7 xx0317376
700    1_
$a Bachy, E $u Hospices Civils de Lyon, Pierre-Benite, France.
700    1_
$a Malladi, R $u Centre for Clinical Haematology, Birmingham, UK.
700    1_
$a Orchard, K $u Southampton General Hospital, Southampton, UK.
700    1_
$a Pohlreich, D $u Charles University Hospital, Prague, Czech Republic.
700    1_
$a Tilly, H $u Centre Henri Becquerel, Rouen, France.
700    1_
$a Bonifazi, F $u Bologna University, S. Orsola-Malpighi Hospital, Bologna, Italy.
700    1_
$a Poiré, X $u Cliniques Universitaires St Luc, Brussels, Belgium.
700    1_
$a Guilhot, F $u CHU, Poitiers, France.
700    1_
$a Haenel, A $u Klinikum Chemnitz gGmbH, Chemnitz, Germany.
700    1_
$a Crawley, C $u Addenbrookes Hospital, Cambridge, UK.
700    1_
$a Metzner, B $u University Clinic for Internal Medicine-Oncology and Haematology, Klinikum Oldenburg, Oldenburg, Germany.
700    1_
$a Gribben, J $u Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
700    1_
$a Russell, N H $u Nottingham City Hospital, Nottingham, UK.
700    1_
$a Damaj, G $u CHU, Amiens, France.
700    1_
$a Thomson, K $u University College London Hospital, London, UK.
700    1_
$a Dreger, P $u EBMT LWP Office, Paris, France. Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
700    1_
$a Montoto, S $u EBMT LWP Office, Paris, France. Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 52, č. 8 (2017), s. 1120-1125
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28530668 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20240516121144 $b ABA008
999    __
$a ok $b bmc $g 1317133 $s 1021923
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 52 $c 8 $d 1120-1125 $e 20170522 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Archiving options